Research programme: Alzheimer's disease vaccines - Mindset Biopharmaceuticals
Alternative Names: AmyrexLatest Information Update: 08 Jul 2013
At a glance
- Originator New York University School of Medicine
- Developer Mindset BioPharmaceuticals; New York University School of Medicine
- Class Alzheimer vaccines; Antidementias; Neuroprotectants
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 08 Jul 2013 No development reported - Preclinical for Alzheimer's disease in Israel (unspecified route)
- 08 Jul 2013 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
- 06 Mar 2008 Preclinical development for Alzheimer's disease is ongoing in Israel